Farmaceutisk IBM · Koreansk KFDA GMP · Korea Ever-Power
Sprøjtestøbning er processtandarden for koreansk farmaceutisk primær emballage i HDPE og PP. Det er den eneste blæsestøbningsproces, der konsekvent opfylder de koreanske KFDA GMP-dimensionskrav til CRC-beholdere uden sekundær halsbearbejdning, eliminerer risikoen for partikelforurening fra flashtrimning og opnår det antal hulrum, der kræves til koreansk farmaceutisk produktionsøkonomi i formater på 10-100 ml. Denne vejledning dækker beholderformater, koreansk KFDA-kvalificering, halspræcision, overvejelser vedrørende renrum og maskinvalg til koreansk farmaceutisk IBM-produktion.
Korea Ever-Power Engineering Desk · Ansan-si · Juli 2026
Farmaceutisk IBM — Koreansk produktionsreference
±0,05 mm
IBM-hals OD-tolerance — koreansk KFDA CRC-kvalifikationsstandard ±0,06 mm
Nul blink
Ingen trimstation — ingen partikelrisiko i koreansk farmaceutisk renrum
Op til 30
Maks. hulrum ved 10 ml — koreansk farmaceutisk megaskala IBM (ZQ135)
KFDA · ICH
Tilpasning af IBM-containerkvalifikationsrammer for koreanske farmaceutiske produkter
Injection blow molding has established itself as the process standard for Korean pharmaceutical primary packaging in HDPE and PP through the convergence of three process advantages that are uniquely relevant to Korean pharmaceutical production requirements. First, injection-moulded neck precision: IBM produces the bottle neck by injection moulding — the same precision manufacturing process that produces pharmaceutical closure components — achieving ±0.05 mm neck OD tolerance consistently across all cavities and all production cycles. This precision is the enabling capability for Korean pharmaceutical CRC containers, dropper-cap bottles and pump-dispenser primary containers, all of which require closure engagement at dimensional tolerances that extrusion blow molding cannot achieve without secondary neck processing. Second, zero flash and zero particulate generation: IBM produces no flash at any stage of the process, which means no trim station, no mechanical trimming operation, and no plastic particles generated in the production environment. For Korean pharmaceutical cleanroom production where particulate control is a GMP requirement, IBM’s inherent particle-free process is a direct regulatory compliance advantage over EBM. Third, multi-cavity efficiency: IBM’s sprøjtestøbningsmaskine Platforme opnår op til 30 kaviteter ved 10 ml — kavitetsantal, der muliggør en økonomi i koreansk farmaceutisk produktion i enkeltmaskineskala, som EBM ikke kan opnå i små formater.
Produktionen af farmaceutiske beholdere i Korea er yderligere drevet af specifikke koreanske lovgivningsmæssige krav. De koreanske KFDA (Ministeriet for Fødevare- og Lægemiddelsikkerhed) regler for farmaceutiske beholdere kræver dokumentation for beholderkvalificering, der omfatter dimensionsmæssig overholdelse, kemisk kompatibilitet, data om ekstraherbare og udvaskbare stoffer samt test af lukkefunktioner – alle disse IBM-beholdere gennemgår etablerede kvalifikationsprotokoller. Koreanske farmaceutiske mærker, koreanske kontraktproducenter og koreanske farmaceutiske eksportører specificerer alle IBM-beholdere til deres farmaceutiske primæremballage i små formater som følge af denne lovgivningsmæssige og kvalitetsmæssige tilpasning.
Krav til koreanske primære farmaceutiske beholdere er fastsat af den koreanske KFDA (식품의약품안전처) i henhold til den koreanske lov om farmaceutiske anliggender og den koreanske farmakopé (KP). Koreanske krav til farmaceutiske beholdere stemmer i det væsentlige overens med ICH Q6A-specifikationer og USP/EP-standarder for plastbeholdere med koreanske tilføjelser for visse beholderformattyper. Koreanske producenter af farmaceutiske IBM-beholdere skal forstå, hvilke KFDA-krav der gælder for deres specifikke beholderformater, før de påbegynder den koreanske farmaceutiske kvalifikationsproces.
Den koreanske farmakopé (KP) generelle monografi for plastikbeholdere til farmaceutisk brug specificerer testkrav til farmaceutiske HDPE- og PP-beholdere, herunder: ekstraherbare stoffer under KP-grænserne i vand, 4%-eddikesyre, ethanol 20%, heptan- og methanolekstraktionsmedier; tungmetaller under 1 ppm; phenol under 5 ppm; UV-absorbans inden for grænserne. IBM-beholdere skal bestå disse test ved den specificerede vægtykkelse ved hjælp af produktionskvaliteten af HDPE- eller PP-harpiks – ikke en laboratorietestprøve. Koreanske farmaceutiske IBM-producenter bør udføre test af ekstraherbare stoffer på faktiske produktionsbeholdere fra deres IBM-maskine under deres produktionsforhold ved hjælp af harpiks fra samme kommercielle parti, der skal levere til produktionen, for at sikre, at testresultaterne repræsenterer det kommercielle produkt, som koreanske farmaceutiske mærker vil validere.
Den koreanske KFDA kræver desuden specifik dimensionsdokumentation for farmaceutiske primære beholdere, der anvendes sammen med registrerede koreanske farmaceutiske produkter. Det koreanske farmaceutiske dossier (koreansk NDA-ækvivalent) indeholder beholderspecifikationer, der dækker: nominelt volumen med fyldningsniveaumærkeposition, halsens ydre diameter og boringsdiameter med tolerancer, specifikation af lukningsmoment, identifikation af beholdermateriale (harpikstype, kvalitet, status som positivliste for koreansk KFDA) og farve (transparent, naturlig HDPE, pigmenteret HDPE, hvis relevant). Enhver ændring af beholderspecifikationen - herunder ændring af harpiksparti, ændring af produktionsmaskine eller ændring af kavitetsantal - kræver en anmeldelse af beholderændring fra den koreanske KFDA og kan kræve fornyet kvalifikationstest afhængigt af ændringens art.
| Containerformat | Koreansk KFDA-nøglekrav | IBMs overholdelsesstatus |
|---|---|---|
| Oftalmisk (øjendråber) | Steril fyldningskompatibilitet, dråbetipstilpasning ±0,05 mm, partikelfri (KFDA injicerbare standard) | Native — injektionshals, nul flash ✓ |
| CRC medicinflaske | CRC-hætteindgreb i henhold til KS M ISO 8317, hals-YD ±0,06 mm, gevind-YD ±0,05 mm | Naturlig — injektionshals ±0,05 mm ✓ |
| Oral flydende hætteglas | Kompatibilitet med induktionstætning, halsfladhed ±0,1 mm, kemisk kompatibilitet 24 måneder | Naturlig — flad halsforseglingsflade ✓ |
| Pumpe Dispenser Primær | Pumpekraveindgreb, halsboring ±0,08 mm, kemisk kompatibilitet | Naturlig — præcision i indsprøjtningshalsboringen ✓ |
| Autoklav PP-beholder | 121°C dampmodstand, dimensionsretention efter autoklav, KP-plasttest | PP IBM — varmebestandig kvalitet kræves ✓ |
HDPE er det dominerende materiale til koreanske farmaceutiske IBM-beholdere – og tegner sig for størstedelen af den koreanske produktion af primære farmaceutiske beholdere i HDPE IBM. Den komplette farmaceutiske HDPE IBM-guide er dækket i HDPE IBM-behandlingsvejledningDette afsnit fokuserer på de farmaceutisk specifikke krav til hvert HDPE IBM-containerformat.
Korean 10 ml HDPE ophthalmic containers are the highest-volume pharmaceutical IBM format in Korea — the combination of Korean ophthalmic prescription volume (Korea has one of East Asia’s highest rates of ophthalmic prescription per capita, driven by Korean contact lens use and Korean digital eye fatigue), Korean OTC artificial tear market and Korean pharmaceutical export requirements produces annual Korean ophthalmic container volume above 500 million units. IBM is the process of record for Korean ophthalmic containers because the dropper tip’s aperture, the dropper cap thread engagement and the container body’s sufficient transparency for fill-level inspection all require IBM’s precision that EBM cannot match. HDPE grade for Korean ophthalmic IBM: MI 0.3–0.5, density 0.950–0.960, pharmaceutical-grade additive package per KFDA positive list. Wall thickness: body 0.30–0.40 mm (sufficient transparency for fill-level check), neck 0.9–1.2 mm (closure retention). Production: Korea Ever-Power ZQ80 (20 cavities → ~15,800/hour) and ZQ110 (24 cavities → ~19,000/hour) are the principal Korean ophthalmic IBM platforms.
Korean 30 ml HDPE oral liquid vials serve unit-dose liquid medications — Korean syrups for paediatric use, Korean liquid vitamin preparations and Korean oral rehydration solutions. These formats require IBM for two specific reasons: the induction seal compatibility of the neck’s flat sealing surface (IBM’s injection mould produces the flat sealing land with Ra ≤ 0.05 μm required for consistent induction seal bonding across all 18–20 cavities) and the fill-level transparency of the HDPE body. At 30 ml, the IBM machine produces 18 cavities on the ZQ80 (approximately 16,200 vials per hour) or up to 22 cavities on the ZQ110 (approximately 19,800 vials per hour) — output rates that match Korean oral liquid pharmaceutical production line speeds without requiring multiple IBM machines for a single product line.
Korean CRC medicine bottles in HDPE at 100 ml are the most demanding pharmaceutical IBM format from a dimensional tolerance perspective. Korean KS M ISO 8317 child-resistant closure testing requires that less than 20% of adult test subjects fail to open the container within 5 minutes (CRC must be child-resistant but adult-accessible). This functional balance is achieved by the CRC cap’s mechanical engagement with the bottle neck’s engagement bead — an engagement that depends on the bead OD being within ±0.06 mm of the CRC cap’s designed engagement diameter. IBM’s ±0.05 mm neck OD tolerance is within this requirement; EBM’s ±0.15–0.25 mm tolerance is not. HDPE grade for CRC IBM: MI 0.5–0.8 for a stiffer bead that resists deformation under CRC cap push-down force; density 0.955–0.965 for maximum bead stiffness at the engagement contact zone.
Polypropylene (PP) is required over HDPE for Korean pharmaceutical IBM containers in two well-defined application categories: terminal steam sterilisation (autoclave) and high-temperature pharmaceutical processes. PP’s heat deflection temperature (110–120°C at 0.45 MPa) allows it to retain dimensional integrity through Korean standard autoclave cycles at 121°C for 20 minutes, whereas HDPE begins to deform above 80–85°C under steam pressure and closure torque.
Korean terminally sterilised pharmaceutical products — including some Korean ophthalmic preparations, Korean irrigating solutions and Korean topical pharmaceutical formulations — require primary containers that survive the autoclave cycle without dimensional change at the closure engagement zone. PP IBM containers for Korean autoclave use specify: PP copolymer grade (homopolymer PP has better heat resistance but is more brittle; random copolymer PP offers better clarity and impact resistance at a slight reduction in heat resistance — for Korean pharmaceutical autoclave at 121°C, either grade is adequate); melt flow rate 5–15 g/10min at 230°C/2.16 kg (higher MFR than HDPE IBM grades, matching PP’s typically higher flowability); barrel temperature 200–240°C on Korea Ever-Power ZQ series machines (higher than HDPE processing, requiring barrel zone setpoints adjusted from the HDPE baseline); dimensional verification post-autoclave (container neck OD and thread dimensions must be within specification after 3 autoclave cycles at 121°C/20 min — this post-autoclave dimensional verification is a KFDA qualification requirement for terminally sterilised Korean pharmaceutical containers).
| Behandlingsparameter | HDPE (MI 0,3–0,8) | PP (MFR 5–15) |
|---|---|---|
| Målezonetemperatur | 200–215°C | 220–235°C |
| Temperatur på indsprøjtningsdysen | 210–220°C | 230–245°C |
| Injektionstryk | 80–140 MPa | 60–110 MPa (lavere viskositet) |
| Blæseopholdstid | 0,8–1,5 sekunder | 1,0–2,0 s (langsommere krystallisation) |
| Formtemperatur | 15–25°C | 20–40 °C (PP skal afkøles langsommere for at forhindre stresshvidning) |
| Dimensionskontrol efter autoklav | Ikke påkrævet | Påkrævet — Koreansk KFDA-kvalifikation |
Pharmaceutical closure function is the most demanding test of IBM neck precision. Every Korean pharmaceutical closure system — CRC caps, dropper tips, induction seals, pump collars and spray actuators — specifies dimensional requirements for the container neck that the closure interacts with. IBM’s ±0.05 mm neck OD tolerance is the process characteristic that allows Korean pharmaceutical IBM containers to pass closure function tests across all cavities simultaneously, at production sampling frequencies, without statistical outliers at the tolerance edges.
Korean CRC containers must pass Korean KS M ISO 8317 child-resistant effectiveness testing — a formal protocol where 200 adult test subjects and 200 child test subjects each attempt to open the container under specified conditions. The mechanical function of the push-and-turn CRC cap depends on its ratchet teeth engaging the neck bead at a specific interference fit: too wide (neck OD too high) and the cap cannot be rotated — adult accessibility fails; too narrow (neck OD too low) and the cap can be rotated without depression — child resistance fails. The tolerance window for the neck engagement bead OD in Korean pharmaceutical CRC containers is typically ±0.06 mm from the CRC cap manufacturer’s specified nominal. IBM’s ±0.05 mm neck OD is within this window; EBM’s ±0.15–0.25 mm exceeds it. At 24-cavity production on a ZQ110, all 24 cavities must individually produce neck OD within the ±0.06 mm window on every cycle — a requirement that IBM meets through its injection-moulded neck insert precision, which holds the neck OD regardless of blow air pressure, cycle time variation or mould cooling variation.
Korean ophthalmic dropper caps use a snap-fit aperture control insert that seats inside the bottle neck bore, with the insert’s outer diameter engaging the bore inner surface at a specific interference. IBM’s injection mould core rod defines the bore inner diameter with ±0.04 mm tolerance — directly translating to ±0.04 mm aperture control insert fit variation. For Korean induction seal containers (30 ml oral liquid, 100 ml multi-dose liquid), the neck’s flat sealing land must be flat within 0.1 mm TIR (total indicator runout) for the induction foil to bond uniformly without gaps. IBM’s injection mould produces the sealing land surface with the same precision as a machined engineering component — flatness ±0.05 mm TIR across all cavities — because the sealing land is formed by the injection mould face rather than by a parting line or pinch-off as in EBM.
Korean pharmaceutical primary container production is increasingly conducted in ISO Class 8 or better cleanroom environments — particularly for ophthalmic containers, injectable primary packaging, and multi-dose liquid containers where particulate contamination in the container before filling is a KFDA pharmaceutical quality risk. IBM’s zero-flash production is a direct cleanroom compliance advantage because the particle generation mechanisms inherent to EBM — the flash trim station’s mechanical cutting, the flash removal conveyor, and the regrind system — are entirely absent from an IBM production cell.
Korean pharmaceutical cleanroom IBM cell design requirements for ISO Class 8 (equivalent to Korean GMP Grade D) container production: the IBM machine’s mould area — where containers are formed and where the output conveyor receives the containers — should be enclosed under HEPA-filtered positive-pressure supply air at a minimum of 0.45 m/s face velocity and 20 air changes per hour. Korea Ever-Power’s ZQ series machines accommodate HEPA enclosure installation by the Korean customer’s HVAC engineering team, with connection points for supply air ductwork identified in the ZQ machine layout drawings provided at order. The IBM machine’s hydraulic system should be filled with pharmaceutical-compatible food-grade hydraulic oil (specified as an option on ZQ80, ZQ110 and ZQ135) to prevent non-compliant mineral oil contamination if any hydraulic system seepage occurs in the cleanroom environment.
Korea Ever-Power’s dual hydraulic system (standard on the ZQ80 and above) provides a secondary cleanroom benefit: its 20–30% energy saving versus single-circuit competitor IBM machines reduces the waste heat load generated per unit of container output in the cleanroom space, which reduces the HVAC cooling demand required to maintain the cleanroom temperature set point (typically 20–22°C for Korean pharmaceutical cleanrooms). For Korean pharmaceutical factories where cleanroom HVAC energy is a significant operating cost, the ZQ80 and above models’ dual hydraulic energy efficiency contributes to reduced HVAC loads per unit of production output — a compounding benefit on top of the direct machine energy saving.
Kvalificering af koreanske farmaceutiske IBM-containere følger en struktureret dokumentationsproces, som koreanske farmaceutiske mærker kræver af deres leverandører af IBM-containere. Forståelse af denne proces giver koreanske IBM-emballageproducenter mulighed for at forberede den korrekte dokumentation på forhånd, hvilket reducerer tidslinjen for kvalificering og undgår forsinkelser i KFDA-indsendelse forårsaget af manglende tekniske data.
Fase 1 — Teknisk fil for container
Materialespecifikationsark (harpiksproducent, kvalitet, MI, densitet, koreansk KFDA-positivlistereference); beholderens dimensionstegning med alle nominelle dimensioner og tolerancer; identifikation af produktionsmaskine og form; adresse på produktionsstedet og status for koreansk KFDA-registreret emballageanlæg (hvis relevant). Korea Ever-Power leverer denne dokumentation som en del af standardleveringspakken til ZQ-serien.
Fase 2 — Test af containerkvalificering
Korean Pharmacopoeia plastic container test results (extractables from Korean accredited laboratory); dimensional measurement report (cavity-by-cavity, 30 measurements per dimension, 3 production batches); closure engagement test (CRC per KS M ISO 8317, induction seal per ASTM F2096 or equivalent Korean standard, dropper tip insertion torque); chemical compatibility compatibility test (12-week filled stability at 40°C/75% RH with the specific pharmaceutical formulation). Korea Ever-Power provides the cavity-by-cavity dimensional report from pre-delivery production trials as part of standard delivery — reducing the Korean customer’s testing burden at Stage 2.
Fase 3 — Koreansk KFDA-containerændringsmeddelelse (hvis relevant)
For koreanske farmaceutiske produkter med eksisterende KFDA-registrering, der bruger en anden beholderleverandør eller beholderspecifikation: Koreansk KFDA-procedure for anmeldelse af beholderændringer i henhold til artikel 32 i den koreanske lov om farmaceutiske anliggender. Mindre ændringer (samme materialeklasse, samme beholdertype, inden for den oprindelige dimensionstolerance) kan selvdeklareres af den koreanske farmaceutiske producent. Større ændringer (materialeændring, ændring af lukketype, ændring af dimensionstolerance) kræver koreansk KFDA-gennemgang og godkendelse før kommerciel produktionsbrug. Tidslinje: selverklæring vedrørende mindre ændringer = øjeblikkelig; større KFDA-gennemgang af ændringer = 3-6 måneder ved den nuværende koreanske KFDA-gennemgangshastighed.
Udvælgelse af koreanske farmaceutiske IBM-maskiner følger den samme årlige volumenramme som andre IBM-applikationer, med én yderligere overvejelse specifik for farmaceutisk produktion: Koreansk GMP-leverandørkvalificering kræver kvalifikation på en specifik maskine (identificeret ved maskinens serienummer) og antal kaviteter. Skift til en maskine med højere kavitet efter den indledende kvalificering kræver genoptagelse af kvalifikationen – en omkostnings- og tidsmæssig overvejelse, der gør det indledende maskinvalg i den korrekte skala vigtigere for farmaceutiske IBM end for husholdningskemikalier, hvor formatfleksibiliteten er højere, og kravene til genoptagelse af kvalifikationen er mindre krævende.
| Årlig volumen (10 ml farmaceutisk) | ZQ-model | Hulrum @10 ml | Koreansk farmaceutisk profil |
|---|---|---|---|
| Under 15 mio. / år | ZQ40 | 9 | Koreansk farmaceutisk startup, levering af koreansk materiale til kliniske forsøg, koreansk speciale i sjældne sygdomme |
| 15–30 mio. / år | ZQ60 | 14 | Koreansk mellemstor farmaceutisk virksomhed, koreansk regional hospitalsforsyning, koreansk håndkøbsmedicinsk beholder |
| 30–50 millioner / år | ZQ80 | 20 | Stor koreansk farmaceutisk virksomhed, koreansk kontraktemballage til farmaceutisk virksomhed, koreansk farmaceutisk eksportør |
| 50–65 millioner / år | ZQ110 | 24 | Koreansk storskala kontraktfarmaceutisk emballage, koreansk multiproduktfarmaceutisk |
| Over 65 mio. / år | ZQ135 | 30 | Koreansk national farmaceutisk producent, koreansk hospitalsforsyningskæde kontraktemballage |
Strategi for genopretning af koreansk farmaceutisk IBM-opskalering: Korean pharmaceutical IBM producers who anticipate scale-up from ZQ60 to ZQ80 within 3 years should consider qualifying both machines simultaneously at initial installation — qualifying the ZQ60 as the primary production machine and the ZQ80 as the approved secondary machine in the same Korean KFDA container change notification. This pre-emptive dual-machine qualification adds modest documentation cost at initial qualification but avoids the 3–6 month Korean KFDA review period for the machine change notification when the scale-up occurs. Korea Ever-Power’s pharmaceutical application team advises Korean pharmaceutical IBM customers on dual-machine qualification strategy as part of the pre-purchase application consultation for pharmaceutical production lines.
Q1 — Hvilken koreansk KFDA-dokumentation kræves for at kvalificere sig som leverandør af farmaceutiske beholdere til IBM?
Koreanske farmaceutiske mærker, der kvalificerer en ny IBM-containerleverandør, kræver en dokumentationspakke, som Korea Ever-Power leverer som standard med hver farmaceutisk IBM-levering. Den komplette pakke inkluderer: (1) Harpiksspecifikation - producent, kvalitetsbetegnelse, lotnummer, analysecertifikat inklusive MI, densitet, smeltepunkt og koreansk KFDA-positivlistereference eller KFDA-fødevare-/farmaceutisk kontaktdeklaration; (2) Containertegning - alle nominelle dimensioner og tolerancer, materialeidentifikation, volumenmærkningsspecifikation og revisionshistorik; (3) Maskin- og formidentifikation - Korea Ever-Power-maskinens serienummer, formens serienummer, antal hulrum og adresse på produktionsstedet; (4) Dimensionsrapport for hulrum - 30 målinger pr. dimension (hals-YD, boringsdiameter, højde, volumen) på tværs af alle hulrum fra 500 på hinanden følgende produktionscyklusser, der verificerer, at alle hulrum er inden for specifikationen samtidigt; (5) Korean Pharmacopoeia-testcertifikat for plastbeholdere - ekstraherbare materialer fra koreansk akkrediteret testlaboratorium, der bekræfter overholdelse af KP-grænseværdier for farmaceutiske HDPE- eller PP-beholdere; (6) Testrapport for lukkeindgreb — CRC-funktion i henhold til KS M ISO 8317 (til CRC-beholdere), induktionsforseglingsbindingsstyrke (til induktionsforseglingsbeholdere) eller indsættelsesmoment for dråbetip (til oftalmiske dråbetip); (7) Kemisk kompatibilitetsrapport — 12-ugers fyldningsstabilitet ved 40°C/75% RF ved brug af den specifikke farmaceutiske formulering hos den foreslåede beholderleverandør, der bekræfter, at der ikke kan ekstraheres stoffer over KFDA-grænserne, ingen dimensionsændring over specifikationen og ingen fejl i lukningens integritet. Tidslinjen fra levering af IBM-maskinen til færdiggørelse af den fulde dokumentationspakke er typisk 16-20 uger, når alle tests forløber parallelt — 12-ugers fyldningsstabilitetstesten styrer den samlede tidslinje.
Q2 — Hvordan eliminerer IBM risikoen for partikelforurening i koreansk farmaceutisk renrumsproduktion?
IBM eliminates particulate contamination risk in Korean pharmaceutical cleanroom production through its fundamental process architecture — not through add-on contamination control measures. Three specific particle generation mechanisms present in EBM are absent from IBM: the flash trim station (where mechanical blades contact the bottle at high speed to remove flash, generating plastic particles that become airborne in the production environment); the flash removal conveyor (where flash pieces are conveyed away from the blow station, and fragmentation of flash pieces in the conveyor generates secondary plastic particles); and the regrind system (where flash is granulated into regrind particles for return to the extruder, and the granulator generates fine plastic dust). In an IBM production cell, none of these mechanisms exist. The IBM machine produces finished containers directly from resin without any intermediate product (flash) that requires mechanical processing. In a Korean pharmaceutical cleanroom IBM cell, the only particle sources are: resin dust from the hopper (controlled by enclosed hopper with filtered vent); mould core rod wear particles (controlled by periodic core rod inspection and replacement schedule); and hydraulic system particles (controlled by hydraulic filter maintenance and pharmaceutical-grade oil specification). All three can be managed to Korean pharmaceutical cleanroom particulate limits with standard cleanroom housekeeping protocols. Korea Ever-Power’s ZQ series pharmaceutical machine configuration includes hydraulic oil filter grade specification and maintenance interval recommendations that keep hydraulic particle contribution below Korean pharmaceutical cleanroom particulate action limits.
Q3 — Hvad er det maksimale antal kaviteter, der er tilgængelige for IBM-produktion af koreanske farmaceutiske CRC-beholdere?
The maximum cavity count for Korean pharmaceutical CRC container IBM production on Korea Ever-Power’s ZQ series depends on the container volume. For 100 ml CRC medicine bottles (the most common Korean pharmaceutical CRC format): 14 cavities on the ZQ110 (confirmed production configuration). For 50 ml CRC containers: up to 18 cavities on the ZQ110. For 30 ml CRC vials: up to 22 cavities on the ZQ110 or up to 26 cavities on the ZQ135. The CRC container maximum cavity count is determined by the platen size and 1,100–1,350 KN injection clamping force requirements — at 100 ml CRC, the larger bottle footprint limits the cavity count more than the clamping force per cavity. At 100 ml with 14-cavity ZQ110 production, output is approximately 6,000 CRC medicine bottles per hour at 4-second cycle and 88% efficiency — approximately 12.6 million CRC medicine bottles per Korean two-shift year. Korean pharmaceutical manufacturers producing single-product annual volumes above 12 million 100 ml CRC bottles should evaluate the ZQ135 at a configuration Korea Ever-Power’s pharmaceutical application engineers can size for the specific container dimensions and annual production requirement. For smaller CRC formats at higher cavity counts, the ZQ135 at 24-cavity 50 ml CRC produces approximately 10,800 containers per hour — approximately 22.7 million 50 ml CRC bottles per Korean two-shift year from a single machine.
Q4 — Hvor lang tid tager kvalificering af koreanske farmaceutiske IBM-containere fra maskinordre til godkendelse af kommerciel produktion?
Tidslinjen for kvalificering af IBM-containere til koreanske farmaceutiske produkter fra maskinordre til KFDA-godkendt kommerciel produktion har to faser med forskellige tidslinjer. Fase 1 — Levering og installation af maskiner og forme: 80-100 dage fra ordrebekræftelse (ZQ80 standardlevering 65-80 dage med maskinproduktion + 50-65 dage med parallel formproduktion + installation). Fase 2 — Containerkvalificering og koreansk KFDA-dokumentation: 16-24 uger fra første produktionsprøve. Tidslinjen for fase 2 er domineret af tre aktiviteter, der skal køre i rækkefølge. For det første, testning af koreanske KP-ekstraherbare materialer: 4-6 uger på et koreansk akkrediteret testlaboratorium (samtidig med anden testning). For det andet, testning af fyldt stabilitet: 12 uger ved 40°C/75% RH ved brug af den faktiske farmaceutiske formulering — dette er den kritiske sti-aktivitet, der ikke kan accelereres. For det tredje, notifikation om ændring af koreanske KFDA-containere (hvis påkrævet for et eksisterende registreret koreansk farmaceutisk produkt): 3-6 måneder til gennemgang af større ændringer. Den samlede tidslinje fra maskinordre til kommerciel produktion af et nyt koreansk farmaceutisk produkt (ingen eksisterende KFDA-registrering): cirka 7-9 måneder. For et eksisterende koreansk registreret farmaceutisk produkt, der kræver en anmeldelse af beholderændring: cirka 13-15 måneder (10 måneder fra maskinordre til fuldstændig dokumentation + 3-5 måneders KFDA-gennemgang). Koreanske farmaceutiske mærker, der planlægger IBM-containerovergange, bør indarbejde denne tidslinje i deres koreanske projektplan for emballageændring — IBM-containerkvalificering er ikke på tidslinjen for maskinens levering, men på tidslinjen for den lovgivningsmæssige gennemgang, og den lovgivningsmæssige del kan ikke komprimeres, uanset hvor hurtigt maskinen installeres, og dokumentationen samles.
Q5 — Kan IBM-beholdere opfylde de koreanske KFDA-krav til sterile farmaceutiske produkter?
IBM containers can serve as primary packaging for Korean sterile pharmaceutical products in specific configurations, with the sterility being provided by the filling process rather than the container. For Korean terminally sterilised ophthalmic preparations (eye drops sterilised in the final container by autoclaving or radiation): HDPE IBM containers are compatible with gamma and ethylene oxide sterilisation; PP IBM containers are compatible with steam (autoclave), gamma and EtO sterilisation. The container must be qualified with the specific sterilisation method — dimensional retention through sterilisation cycles, extractables post-sterilisation within KP limits, and closure integrity post-sterilisation. For Korean aseptically filled sterile pharmaceuticals (filled under sterile conditions without terminal sterilisation): the IBM container is not sterile at the point of fill — it must be sterilised before aseptic filling by the Korean pharmaceutical manufacturer. Korean aseptic IBM container sterilisation methods include: gamma irradiation at 25–40 kGy (HDPE and PP both compatible; verify dimensional retention and extractables post-irradiation with the specific resin grade); ethylene oxide (compatible with both HDPE and PP; EtO residuals must desorb to below Korean MFDS medical device limits before use); hydrogen peroxide vapour sterilisation (compatible with HDPE and PP for surface sterilisation of pre-formed containers; used in Korean pharmaceutical blow-fill-seal adjacent processes). IBM containers are not self-sterilising — the Korean pharmaceutical manufacturer is responsible for container sterilisation as part of their Korean GMP pharmaceutical production process validation, with the IBM container supplier’s role being to provide containers that maintain integrity and extractable compliance through the sterilisation method.
Q6 — Hvad er forskellen mellem primær og sekundær farmaceutisk emballage i den koreanske IBM-produktionssammenhæng?
In Korean pharmaceutical packaging regulation, primary packaging is the packaging that is in direct contact with the pharmaceutical product — the HDPE or PP IBM bottle that contains the eye drops, oral liquid, or medicine. Secondary packaging is the outer packaging that surrounds the primary container — the cardboard carton, the blister tray, or the shipper box. IBM containers are pharmaceutical primary packaging, subject to the full Korean KFDA pharmaceutical container qualification requirements described in this guide. Secondary packaging is not subject to Korean KFDA pharmaceutical plastic container standards — only general Korean packaging material standards apply. The primary/secondary distinction matters for Korean IBM packaging producers in two practical ways. First, regulatory pathway: primary container changes (material, supplier, dimensions) require Korean KFDA notification per Korean Pharmaceutical Affairs Act Article 32; secondary packaging changes are typically handled through the Korean pharmaceutical manufacturer’s internal change control process without Korean KFDA notification. Second, cleanroom requirement: Korean pharmaceutical primary container production (IBM containers) is subject to Korean GMP cleanroom environmental requirements; secondary packaging production is not. Korean IBM producers supplying pharmaceutical primary containers must demonstrate Korean GMP-compliant production conditions (environmental monitoring, personnel hygiene, validated cleaning procedures) that secondary packaging producers — such as Korean carton printers — are not required to demonstrate. This distinction explains why Korean pharmaceutical primary container IBM production is typically conducted in dedicated cleanroom production areas separated from the Korean IBM producer’s general commercial packaging production operations.
Farmaceutisk IBM-forespørgsel
Korea Ever-Power leverer dimensionskvalificering af farmaceutiske IBM-containere, koreanske KFDA-dokumentationspakker, konfiguration af renrumsmaskiner og maskinvalg i ZQ-serien til koreansk farmaceutisk primæremballage i alle produktionsskalaer.
Relaterede ressourcer
IBM PHARMACEUTICAL TABLET BOTTLE · PP HDPE OTC RX · CRC INDUCTION SEAL · KOREA…
IBM HAIR CARE BOTTLE · PP PCTG SHAMPOO CONDITIONER · K-BEAUTY OEM · KOREA EVER-POWER…
IBM CYCLE TIME · ZQ MACHINE PARAMETERS · COOLING DWELL · PP HDPE PCTG ·…
IBM MOULD STEEL · H13 P20 S136 TOOLING · HARDNESS POLISHABILITY · SERVICE LIFE ·…
IBM NECK FINISH STANDARDS · GPI BPF PCO THREAD · CRC FITMENT · NECK OD…
IBM DISINFECTANT BOTTLE · PP HDPE ANTISEPTIC · HAND SANITISER · ETHANOL · KOREA EVER-POWER…